Parkman Healthcare Partners’s Cogent Biosciences COGT Stock Holding History

Parkman Healthcare Partners’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.81M	Buy	253,365 +153,239	+153%	+$5.36M	1%	40
2026 Q1	$3.85M	Buy	+100,126	New	+$3.7M	0.4%	68
2024 Q1	–	Sell	-96,837	Closed	-$569K	–	104
2023 Q4	$569K	Sell	96,837 -96,800	-50%	-$742K	0.08%	87
2023 Q3	$1.89M	Buy	193,637 +7,855	+4%	+$93.2K	0.35%	78
2023 Q2	$2.2M	Buy	185,782 +3,886	+2%	+$44.6K	0.38%	73
2023 Q1	$1.96M	Buy	181,896 +40,314	+28%	+$516K	0.43%	57
2022 Q4	$1.64M	Sell	141,582 -95,115	-40%	-$1.18M	0.44%	61
2022 Q3	$3.53M	Sell	236,697 -52,053	-18%	-$713K	1%	37
2022 Q2	$2.6M	Buy	+288,750	New	+$1.97M	0.96%	36

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Parkman Healthcare Partners's COGT Position: Q2 2026 in Review

Parkman Healthcare Partners increased its Cogent Biosciences (COGT) stake by 153% in Q2 2026, buying an estimated $5.36M and bringing the position to 253,365 shares worth $9.81M. The position accounts for 1% of the portfolio, ranked #40.

Parkman Healthcare Partners first reported a position in COGT in Q2 2022 and has held it in 9 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Parkman Healthcare Partners held 253,365 shares of Cogent Biosciences worth $9.81M as of Q2 2026.
Parkman Healthcare Partners bought 153,239 Cogent Biosciences shares in Q2 2026, an estimated $5.36M.
Cogent Biosciences made up 1% of Parkman Healthcare Partners's portfolio in Q2 2026, its #40 holding.
Parkman Healthcare Partners first reported a position in Cogent Biosciences in Q2 2022 and has held it in 9 quarters since.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.